Our strategy is to develop our portfolio of innovative products for two large market categories, sexual health and pain to late stage, and then partner with major pharmaceutical partners at the optimum time to generate most value.
We are investing in our lead product MED2005 to generate most value for shareholders
Completing the first Phase 3 clinical trial and preparing for the second one
Increasing Futura and MED2005’s profile in the medical and investment community
We are focused on innovative products that are highly differentiated in their markets
Delivery of headline data on the first Phase 3 clinical trial for MED2005
We aim to improve treatments to give more choice to patients and doctors and improve the quality of life of those suffering from ED and local pain
Improve clinical trial programme and commercial proposition which will be de–risked with the availability of the headline Phase 3 data
We are focused on increasing value for shareholders and the quality of life for patients.
Increase the profile of MED2005 and value of its unique commercial proposition to potential commercial partners on the back of the anticipated data readout trial data to out–license MED2005.